DDX53 and neoplasm: Descriptions of CT26 neoepitope immunization in the literature report how in one case a single CD4+ T-cell inducing neoepitope could facilitate tumor control25, while another showed that potent tumor control from a group of five primarily MHC class II biased neoepitopes was, surprisingly, completely abrogated upon CD8+ T cell depletion18.